ARA 290 (Cibinetide): Research Overview, Mechanisms, and Current Evidence
ARA 290 (cibinetide) is an 11-amino-acid peptide derived from the B-helix of erythropoietin (EPO). Unlike EPO, it does not stimulate red blood cell production. Instead it selectively activates the innate repair receptor (the EPO and CD131 beta-common receptor heterocomplex), which has been studied in preclinical and early clinical research for tissue protection, anti-inflammatory effects, and neuropathic pain. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
In preclinical models, ARA 290 has been reported to act through the innate repair receptor to support tissue protection without the erythropoietic (red blood cell) effects of EPO.
- Selectively activates the innate repair receptor (EPO and CD131 beta-common receptor) without stimulating erythropoiesis.
- Reduces pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-1-beta in experimental settings.
- Limits apoptosis (programmed cell death) and oxidative stress in tissue-injury models.
- Reported to bias receptor signaling toward the PI3K to AKT pathway associated with cell survival.
Areas of Research Interest
Published studies have examined ARA 290 in the following research contexts. Most evidence is preclinical, with early-phase human trials in neuropathic conditions.
Neuropathic pain and small fiber neuropathy
Investigated in early human trials for conditions such as diabetic and sarcoidosis-associated neuropathy.
Nerve protection and repair
Studied in animal models of peripheral nerve injury and cerebral ischemia for neuroprotective effects.
Anti-inflammatory and organ protection
Examined in models of kidney injury and inflammation for cytoprotective activity.
Transplant and metabolic models
Studied in islet transplantation models for effects on graft inflammation and survival.
Reported Study Parameters
For laboratory research use only. The table below reports the doses and routes used in specific published studies, with sources. It describes what researchers administered in these models and is not a protocol, recommendation, or guidance for use in humans or animals. Animal-study doses are expressed per kilogram of body weight.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| Islet allograft transplantation (mouse) | ~120 µg/kg per day, subcutaneous, 14 days | Yao 2020·DOI |
| Cisplatin-induced kidney injury (cell culture) | 50 to 400 nM, in vitro | Ghassemi-Barghi 2022·DOI |
| Human research | Investigated in early-phase trials for neuropathic conditions; no validated regimen established | Rendell 2021 |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2024 to 2026)
Recent peer-reviewed literature indexed on PubMed continues to characterize how ARA 290 works while clarifying how early the human evidence remains.
Engineered EPO derivatives for brain injury
A 2026 review of erythropoietin-derived compounds, including cibinetide, describes how structural changes bias signaling toward the PI3K to AKT survival pathway and away from red-cell stimulation, and calls for controlled studies to establish safety and timing. PubMed·DOI
Peripheral nerve injury
A 2024 review of EPO and its derivatives reports that ARA 290 shows neuroprotective effects in nerve-injury models, while noting its short half-life as a limitation that has prompted development of modified analogs. PubMed·DOI
Cerebral ischemia (stroke model)
A 2024 mouse study reported that ARA 290 reduced neuronal apoptosis and inflammatory markers after experimental stroke, acting through the beta-common receptor without stimulating red blood cell production. PubMed·DOI
Kidney protection (in vitro)
A 2022 study reported that ARA 290 reduced markers of apoptosis, oxidative stress, and inflammation in a cell model of cisplatin-induced kidney injury, consistent with a cytoprotective mechanism. PubMed·DOI
Research Questions
How does ARA 290 differ from erythropoietin (EPO)?
ARA 290 is derived from a region of EPO but is designed to trigger tissue-protective signaling through the innate repair receptor without stimulating red blood cell production, which is EPO's primary clinical effect.
What is the current state of human evidence?
Human research consists of early-phase trials in neuropathic conditions such as diabetic and sarcoidosis-associated neuropathy. No regimen has been validated for general use.
What does the available safety literature suggest?
Early trials have generally reported tolerability without the thrombotic concerns associated with EPO, but the human data set is small and long-term safety has not been established.
Referenced Citations
Literature indexed on PubMed.
- Sun, Y., et al. (2026). Phase-targeted erythropoietin derivatives for traumatic brain injury. Front. Neurol., 16, 1665405. PubMed·DOI
- Liu, G., et al. (2024). The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury. Int. Immunopharmacol., 138, 112452. PubMed·DOI
- Wang, R.L., et al. (2024). Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the beta-common receptor in cerebral ischemic stroke. CNS Neurosci. Ther., 30(3), e14676. PubMed·DOI
- Ghassemi-Barghi, N., et al. (2022). Protective effect of ARA290 against cisplatin-induced nephrotoxicity. Inflammation, 46(1), 342-358. PubMed·DOI
- Yao, M., et al. (2020). Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 104(10), 2048-2058. PubMed·DOI
- Rendell, M.S. (2021). The time to develop treatments for diabetic neuropathy. Expert Opin. Investig. Drugs, 30(2), 119-130. PubMed·DOI
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.